Methods and Compositions for Treating Esophageal Diseases
AssigneeProfessional Compounding Centers of America
InventorChris V. Simmons
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating esophageal diseases are disclosed. More specifically, these methods may refer to the treament of esophageal varices and eosinophilic esophagitis using an oral suspension drug for humans. The oral suspension drug may include poloxamer f127 used as vehicle and budesonide as a corticosteroid. Poloxamer oral suspension may be administrated by swallowing the poloxamer oral suspension drug which may slide down through the esophageal and may be adhered in the affected site providing a longer residence time. Additionally, poloxamer oral suspension may be mixed with APIs such as antifungals, antibacterials, and corticosteroids, previously dissolved in a suitable liquid, such as water.
Claims18
A pharmaceutical composition for oral administration comprising
- (a) budesonide in a concentration of about 1 mg/10 ml to about 2 mg/10 ml;
- and
- (b) about 5% to about 10% by weight poloxamer f127;
- (c) imidurea;
- and
- (d) optionally, an antimicrobial agent selected from the group consisting of methyl ester of p-hydroxybenzoic acid, propyl ester of p-hydroxybenzoic acid, sodium benzoate, sorbic acid, and combinations thereof.
A method of treating esophageal disease, comprising orally delivering to a patient an effective amount of a pharmaceutical composition that comprises budesonide and at least one poloxamer.
6-8. (canceled)
(canceled)
Dependencies are inferred from the claim text.